Corbus Pharmaceuticals Holdings, Inc. (CRBP) Current Ratio
- Current ratio · latest quarter: Value 5.71×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.71× | Current assets / current liabilities. $122.75M ÷ $21.48M ≈ 5.71× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 122.75M USD | Assets, Current |
| Current obligations | 21.48M USD | Liabilities, Current |
| Cash and equivalents | 23.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.25M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $122.75M | $21.48M | $23.37M | (m) | (m) | (m) | $5.25M | (m) | 5.71× |
| 2026-03-31 | $143.57M | $18.14M | $25.66M | (m) | (m) | (m) | $435.00K | (m) | 7.92× |
| 2025-12-31 | $166.95M | $20.69M | $28.49M | (m) | (m) | (m) | $2.21M | (m) | 8.07× |
| 2025-09-30 | $107.57M | $17.06M | $26.98M | (m) | (m) | (m) | $2.74M | (m) | 6.31× |
| 2025-06-30 | $122.83M | $13.33M | $20.04M | (m) | (m) | (m) | $3.99M | (m) | 9.21× |
| 2025-03-31 | $137.36M | $11.62M | $18.90M | (m) | (m) | (m) | $4.07M | (m) | 11.82× |
| 2024-12-31 | $152.98M | $11.82M | $17.20M | (m) | (m) | (m) | $4.79M | (m) | 12.94× |
| 2024-09-30 | $160.89M | $11.63M | $19.42M | (m) | (m) | (m) | $2.89M | (m) | 13.84× |
| 2024-06-30 | $148.31M | $23.98M | $23.69M | (m) | (m) | (m) | $1.15M | (m) | 6.18× |
| 2024-03-31 | $121.70M | $25.92M | $14.10M | (m) | (m) | (m) | $2.08M | $12.76M | 4.69× |
| 2023-12-31 | $23.55M | $31.89M | $13.72M | (m) | (m) | (m) | $3.18M | (m) | 0.74× |
| 2023-09-30 | $31.21M | $31.54M | $11.25M | (m) | (m) | (m) | $4.71M | $17.85M | 0.99× |
| 2023-06-30 | $38.27M | $16.39M | $8.35M | (m) | (m) | (m) | $1.51M | $7.02M | 2.34× |
| 2023-03-31 | $45.86M | $14.36M | $7.32M | (m) | (m) | (m) | $1.32M | $5.01M | 3.19× |
| 2022-12-31 | $60.18M | $12.64M | $17.00M | (m) | (m) | (m) | $2.17M | $2.80M | 4.76× |
| 2022-09-30 | $67.35M | $17.47M | $12.44M | (m) | (m) | (m) | $1.37M | $9.88M | 3.86× |
| 2022-06-30 | $75.24M | $15.63M | $25.77M | (m) | (m) | (m) | $1.99M | $7.47M | 4.81× |
| 2022-03-31 | $88.48M | $15.12M | $57.03M | (m) | (m) | (m) | $2.70M | $5.18M | 5.85× |
| 2021-12-31 | $100.20M | $17.01M | $25.01M | (m) | (m) | (m) | $1.78M | $3.09M | 5.89× |
| 2021-09-30 | $111.67M | $17.14M | $37.12M | $69.74M | (m) | (m) | $2.55M | (m) | 6.51× |
| 2021-06-30 | $111.58M | $18.74M | $36.08M | $70.37M | (m) | (m) | $1.88M | (m) | 5.96× |
| 2021-03-31 | $130.29M | $23.61M | $66.61M | $57.40M | (m) | (m) | $3.62M | (m) | 5.52× |
| 2020-12-31 | $92.07M | $31.90M | $85.43M | (m) | (m) | (m) | $7.38M | (m) | 2.89× |
| 2020-09-30 | $85.36M | $41.40M | $81.87M | (m) | (m) | (m) | $11.08M | (m) | 2.06× |
| 2020-06-30 | $88.02M | $42.09M | $63.47M | (m) | (m) | (m) | $12.70M | (m) | 2.09× |
| 2020-03-31 | $54.66M | $34.65M | $46.62M | (m) | (m) | (m) | $9.96M | (m) | 1.58× |
| 2019-12-31 | $38.15M | $34.89M | $31.75M | (m) | (m) | (m) | $11.09M | (m) | 1.09× |
| 2019-09-30 | $57.54M | $30.55M | $54.85M | (m) | (m) | (m) | $6.19M | (m) | 1.88× |
| 2019-06-30 | $75.39M | $29.44M | $73.15M | (m) | (m) | (m) | $7.49M | (m) | 2.56× |
| 2019-03-31 | $92.82M | $52.04M | $89.92M | (m) | (m) | (m) | $8.96M | (m) | 1.78× |
| 2018-12-31 | $44.24M | $18.09M | $41.75M | (m) | (m) | (m) | $6.35M | (m) | 2.45× |
| 2018-09-30 | $58.46M | $16.93M | $55.66M | (m) | (m) | (m) | $6.15M | (m) | 3.45× |
| 2018-06-30 | $67.55M | $13.45M | $64.68M | (m) | (m) | (m) | $3.08M | (m) | 5.02× |
| 2018-03-31 | $74.49M | $10.28M | $70.96M | (m) | (m) | (m) | $4.17M | (m) | 7.25× |
| 2017-12-31 | $65.50M | $8.20M | $62.54M | (m) | (m) | (m) | $3.13M | (m) | 7.98× |
| 2017-09-30 | $38.02M | $6.34M | $36.60M | (m) | (m) | (m) | $3.78M | (m) | 6.00× |
| 2017-06-30 | $44.03M | $6.91M | $43.03M | (m) | (m) | (m) | $3.86M | (m) | 6.37× |
| 2017-03-31 | $50.15M | $6.96M | $48.93M | (m) | (m) | (m) | $3.27M | (m) | 7.21× |
| 2016-12-31 | $17.40M | $8.90M | $14.99M | (m) | (m) | (m) | $3.42M | (m) | 1.96× |
| 2016-09-30 | $19.23M | $6.43M | $18.91M | (m) | (m) | (m) | $2.77M | (m) | 2.99× |
| 2016-06-30 | $22.30M | $4.96M | $22.03M | (m) | (m) | (m) | $1.96M | (m) | 4.50× |
| 2016-03-31 | $10.16M | $4.08M | $9.69M | (m) | (m) | (m) | $1.23M | (m) | 2.49× |
| 2015-12-31 | $12.71M | $3.63M | $12.34M | (m) | (m) | (m) | $1.31M | (m) | 3.50× |
| 2015-09-30 | $13.27M | $1.88M | $13.17M | (m) | (m) | (m) | $728.01K | (m) | 7.07× |
| 2015-06-30 | $9.49M | $2.34M | $9.24M | (m) | (m) | (m) | $1.07M | (m) | 4.06× |
| 2015-03-31 | $5.18M | $554.77K | $4.97M | (m) | (m) | (m) | $188.30K | (m) | 9.34× |
| 2014-12-31 | $6.53M | $738.04K | $6.26M | (m) | (m) | (m) | $344.16K | (m) | 8.85× |
| 2014-09-30 | $7.56M | $613.68K | $7.54M | (m) | (m) | (m) | $482.66K | (m) | 12.31× |
| 2013-12-31 | $305.52K | $648.87K | $303.02K | (m) | (m) | (m) | $181.47K | (m) | 0.47× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |